What Is the Survival Rate for a Pituitary Tumor?

The vast majority of people diagnosed with a pituitary tumor survive long term. A large U.S. database study covering more than 46,000 patients found overall survival rates of about 94% at three years, 91% at five years, and 83% at ten years.¹ Those numbers, though, blend together very different tumors with very different behaviors, and the real answer depends heavily on whether your tumor makes excess hormones, how big it is, and how old you are when it is found.

Why the Overall Numbers Can Be Misleading

Pituitary tumors are overwhelmingly benign growths called adenomas. They account for roughly 10–15% of all brain tumors found on imaging, and many are discovered by accident during a scan done for something else entirely. In one 30-year population study, about 37% of pituitary adenomas were found incidentally, meaning the person had no symptoms pointing to the pituitary at all.² Many of those small, incidental tumors never grow or cause trouble, which inflates overall survival statistics. On the other end of the spectrum, a rare malignant form called pituitary carcinoma carries a dramatically worse prognosis. Lumping both groups into a single survival number obscures how different these experiences can be.

A separate single-center study with longer follow-up reported ten-year survival of about 91% and twenty-year survival of roughly 78%, with age at diagnosis as the strongest predictor of who did and did not survive.³ That gradual decline over two decades is not mainly driven by the tumor itself killing people. Instead, the hormonal disruptions these tumors cause, and the treatments used to manage them, create cardiovascular and metabolic risks that accumulate over time. Understanding survival for pituitary tumors means understanding those downstream effects, not just tumor biology.

Non-Functioning Adenomas

Non-functioning pituitary adenomas (sometimes called clinically non-functioning adenomas, or NFPAs) do not secrete excess hormones in a way that causes obvious clinical syndromes. They are the most common subtype and tend to be discovered either incidentally or because they have grown large enough to press on nearby structures, causing headaches or vision problems. Because they lack the hormonal damage that other subtypes inflict, their survival outlook is generally favorable. The main concern is regrowth. After surgery, about 14% of patients in one large Spanish multicenter study experienced tumor progression over a median follow-up of nearly eight years, with residual tumor left after surgery being the strongest predictor.⁴

When NFPAs do regrow after initial treatment, a second regrowth can also happen, though rates depend on what was done the first time around. A study from two large UK centers found that the five-year rate of a second regrowth was about 35% overall, but dropped to roughly 12–13% in patients who received radiotherapy after the first regrowth, compared to over 63% in those who were simply monitored.⁵ So while these tumors rarely threaten life directly, they can require repeated interventions over decades.

Prolactinomas and the Role of Medication

Prolactinomas, tumors that overproduce the hormone prolactin, are the most common functioning pituitary adenomas. They are unusual among brain tumors in that the first-line treatment is medication, not surgery. Drugs called dopamine agonists shrink most prolactinomas and normalize prolactin levels. However, the question of permanent cure is more nuanced than you might expect. A systematic review and meta-analysis found that long-term remission was achieved in about 52% of patients treated with medication alone, compared to 88% of those treated surgically.⁶

That does not mean medication fails in the other half. Many patients do well on lifelong medication and never need surgery. The complication is what happens when you stop taking the drug. A study that followed patients after withdrawing cabergoline found recurrence rates of about 31% in people with small prolactinomas and 36% in those with larger ones over two to five years. Patients whose MRI still showed a tumor remnant at the time of withdrawal had substantially higher recurrence rates than those whose scans were clear.⁷ For survival specifically, prolactinomas are rarely life-threatening. The main long-term issues are managing the tumor’s hormonal effects and dealing with potential regrowth, not mortality.

Growth Hormone-Secreting Tumors and Acromegaly

Tumors that overproduce growth hormone cause a condition called acromegaly, characterized by gradual enlargement of the hands, feet, and facial features. Before modern treatments, acromegaly roughly doubled a person’s risk of premature death compared to the general population, mainly from cardiovascular disease, diabetes complications, and respiratory problems. The good news is that this excess mortality essentially disappears when hormone levels are brought under control. A meta-analysis found that patients whose growth hormone levels were lowered to safe thresholds after treatment had a standardized mortality ratio of 1.1, essentially normal, compared to 1.9 in those whose hormone levels remained elevated.⁸

Treatment has also improved dramatically over time. One single-center study found that the overall standardized mortality ratio for its acromegaly cohort was 1.6 across the entire study period, but when they separated outcomes by era, the ratio was 2.5 before 1992 and 1.0 after 1992, meaning mortality had essentially normalized with modern management.⁹ A broader systematic review and meta-analysis confirmed this trend, finding that mortality in acromegaly has decreased over the last decade, particularly with the more frequent use of medications as add-on therapy after surgery.¹⁰ The takeaway is clear: how long your growth hormone stays elevated matters more for your lifespan than the tumor itself.

ACTH-Secreting Tumors and Cushing’s Disease

Pituitary tumors that produce excess ACTH drive the adrenal glands to flood the body with cortisol, causing Cushing’s disease. This is the pituitary tumor subtype with the most concerning survival implications, because prolonged cortisol exposure damages the cardiovascular system, weakens bones, promotes diabetes, and suppresses the immune system. A systematic review and meta-analysis found that the average standardized mortality ratio for Cushing’s disease patients was about 1.84, meaning nearly double the expected death rate. Critically, patients whose disease persisted after initial surgery had a mortality ratio of 3.73, while those who achieved remission had a ratio that did not differ significantly from the general population.¹¹

Achieving remission quickly matters. A recent study spanning two decades found that patients who did not achieve remission within two years had about a 44% higher mortality risk than those who did.¹² Beyond surgical success, the duration of cortisol exposure before treatment independently raised the risk of death in a large study of 346 patients with Cushing’s disease. Even after successful treatment, depression remained a significant predictor of both death and cardiovascular disease among those who achieved remission.¹³ Among people over 45 at diagnosis, Cushing’s disease patients had a significantly higher mortality risk than acromegaly patients in head-to-head comparisons.³

Pituitary Carcinoma, the Rare Exception

True pituitary carcinoma, defined by the presence of metastases either within the central nervous system or to distant sites, is exceedingly rare. It accounts for a fraction of a percent of all pituitary tumors. Unlike adenomas, carcinomas carry a genuinely poor prognosis. A SEER database study found improved survival compared to historical reports, with one-year, two-year, and five-year overall survival of about 88%, 74%, and 67% respectively.¹⁴ Another study looking specifically at survival from the point of metastasis identification reported more sobering numbers: a median survival of four years, with five-year survival of 37% and eleven-year survival of just 13%.¹⁵

The difference between those two sets of numbers partly reflects when you start counting. The SEER study captured all patients from initial diagnosis, including some diagnosed early, while the second study measured survival from the moment metastases were confirmed. Treatment with temozolomide, a chemotherapy drug, was associated with improved survival in pituitary carcinoma, though the numbers remain small and the prognosis remains guarded.¹⁶ Carcinomas also showed significantly worse overall survival compared to invasive adenomas at one, two, and five years.¹⁷

How Age and Tumor Size Shift the Odds

Across virtually every study, age at diagnosis is the single most consistent predictor of survival. This partly reflects the obvious: older people have shorter remaining lifespans regardless of their pituitary tumor. But it also reflects clinical realities. Elderly patients undergoing pituitary surgery face higher short-term mortality. A study of surgical outcomes found that patients 65 and older had 30-day mortality of about 1.4% compared to 0.6% in younger patients, and 90-day mortality of about 2.8% versus 0.9%.¹⁸ Those are still low numbers in absolute terms, but the relative difference is substantial. Reassuringly, another study looking specifically at transsphenoidal surgery in elderly patients found zero perioperative deaths across its cohort, suggesting that with appropriate patient selection, surgery remains safe even at advanced ages.¹⁹

Tumor size matters because larger tumors are harder to remove completely and more likely to invade surrounding structures. When adenomas grow into the cavernous sinus, the bony channel alongside the pituitary that houses major blood vessels and nerves, the odds of complete surgical removal drop sharply. One study found that cavernous sinus invasion was present in about 23% of cases and reduced gross total resection rates from 86% to 47%, while dramatically increasing the need for additional treatment afterward.²⁰ Incomplete removal, in turn, is one of the strongest predictors of future regrowth and the need for radiation or reoperation.

Children and adolescents with pituitary adenomas generally fare better than adults. A National Cancer Database analysis found that pediatric patients were more likely to achieve complete surgical removal and showed improved five-year and ten-year overall survival compared to adults.²¹

Radiation Therapy and Long-Term Tumor Control

Radiation is typically reserved for tumors that recur after surgery, cannot be completely removed, or do not respond adequately to medication. Its track record for local control is strong. One long-term study reported a ten-year local control rate of 98% for non-secreting adenomas and 73% for hormone-secreting ones, with ten-year cause-specific survival of 95% and 88% respectively.²² Another older series found a ten-year progression-free rate of 96% and cause-specific survival of 97%.²³

More recent data, including newer techniques such as proton therapy, shows five-year local control of about 95%, though this drops to 75% at twenty years. Proton therapy appeared to improve both local control and overall survival compared to older photon-based techniques.²⁴ The major trade-off of radiation is hormone deficiency. Across studies, about 35–40% of patients develop new pituitary hormone deficits after radiation, a complication that may not appear for years or even decades and that requires lifelong hormone replacement. Vision loss, the complication patients worry about most, is rare, occurring in fewer than 3% of patients in modern series.

Why Hormone Deficiency Is the Hidden Survival Issue

Whether caused by the tumor itself, by surgery, or by radiation, damage to the pituitary gland often leaves patients deficient in one or more hormones. This condition, broadly called hypopituitarism, has a direct impact on lifespan. A landmark study found that patients with hypopituitarism had an overall death rate about 73% higher than expected for their age and sex.²⁵ Pituitary disease is associated with increased mortality predominantly due to vascular disease, including heart attacks and strokes.²⁶

Growth hormone deficiency is one of the most common deficits and has attracted particular attention as a treatable risk factor. A study comparing patients who received growth hormone replacement to those who did not found a standardized mortality ratio of 0.65 in the treated group versus 1.16 in the untreated group, a significant difference.²⁷ A meta-analysis cautioned that the evidence is not from randomized trials and may be affected by selection bias (healthier patients being more likely to receive replacement therapy), but concluded that the available data does suggest growth hormone replacement plays a meaningful part in normalizing mortality for these patients.²⁸ The practical implication is that long-term endocrine follow-up and proper hormone replacement matter as much for survival as the initial tumor treatment itself.

Predicting Recurrence

Even after apparently successful treatment, pituitary adenomas can come back. Several factors help predict who faces a higher recurrence risk. Leftover tumor after surgery is consistently the strongest predictor, but pathology findings also help. The Ki-67 labeling index, a measure of how actively tumor cells are dividing, has emerged as a useful tool. One study found that tumors with Ki-67 values above about 2.5% had a significantly higher recurrence risk, with 85% sensitivity for predicting recurrence at that threshold.²⁹ Another study using a slightly different cutoff of 1.3% found that Ki-67 was an independent predictor of progression.³⁰

In non-functioning adenomas specifically, a high Ki-67 index was associated with a significantly higher rate of regrowth: 67% of tumors with Ki-67 of 3% or above regrew compared to 17% of those below that threshold.³¹ Cavernous sinus invasion, visible on MRI, is another reliable marker. Beyond individual biomarkers, a review of the field identified tumor size, immunohistological subtype, postoperative hormone levels, and whether radiation was given after surgery as additional predictive factors.³²

Where You Get Treated Can Matter

Not all hospitals are equally experienced with pituitary surgery, and volume makes a measurable difference. The study of elderly surgical patients found that high-volume facilities had 30-day mortality of 0.9% compared to 1.8% at low-volume centers, and 90-day mortality of 2.0% versus 3.5%.¹⁸ Prolonged hospital stays were also less common at high-volume centers. These differences are significant enough that patients, particularly older ones, should ask about institutional and surgeon volume when considering surgery.

Demographic disparities also affect outcomes, though more through access than biology. A study found that Black and Hispanic patients were more likely to be treated at lower-volume pituitary surgery centers and had higher rates of postoperative complications even after accounting for patient and hospital characteristics.³³ Separately, white patients had somewhat higher odds of receiving surgery compared to non-white patients after adjusting for age, sex, socioeconomic status, and tumor grade, though race was not found to be a significant independent predictor of survival itself once those other factors were accounted for.³⁴

Life After Treatment and Quality of Life

Surviving a pituitary tumor and living well afterward are not the same thing. A systematic review of quality-of-life studies found that patients with active pituitary disease had impaired quality of life compared to healthy controls, and while quality of life generally improved once the hormonal excess was brought under control, it did not fully normalize. Patients with remitted Cushing’s disease showed the least improvement, consistent with the lingering metabolic and psychological effects of prolonged cortisol exposure. Sleep problems, altered illness perceptions, and ongoing hormone deficits all contributed to reduced well-being.³⁵

On a more encouraging note, the surgical procedure itself does not appear to create lasting quality-of-life damage. A five-year follow-up study of patients who underwent endoscopic pituitary surgery found no significant decline in tumor-related or nasal quality-of-life scores over the entire period, regardless of tumor type, size, or whether complete removal was achieved.³⁶ The quality-of-life burden, in other words, comes more from the disease and its hormonal aftermath than from the surgery to treat it. Most research agrees that impaired quality of life is common in pituitary tumor survivors but remains poorly understood in terms of how to prevent or improve it.³⁷

Pituitary Apoplexy

Pituitary apoplexy is a sudden event in which a pituitary tumor bleeds or loses its blood supply, causing an abrupt headache, vision changes, and sometimes hormonal crisis. It sounds alarming, and it is a medical emergency when it happens. But its long-term survival implications are less dire than people often assume. A study of patients with non-functioning adenomas who experienced apoplexy found that their standardized mortality ratio was 1.09, statistically indistinguishable from patients with the same type of tumor who never had apoplexy.³⁸ The catch is that apoplexy frequently damages the normal pituitary gland: only about a quarter of patients in that study had fully normal pituitary function after the event, while the rest needed some degree of lifelong hormone replacement. It is the resulting hormone deficiencies, not the apoplexy itself, that shape long-term health.

1
Scientific Reports. Incidence, demographics, and survival of patients with primary pituitary tumors: a SEER database study in 2004–2016
2
ScienceDirect. Pituitary Adenoma Incidence, Management Trends, and Long-term Outcomes: A 30-Year Population-Based Analysis
3
PubMed Central. Comparative mortality in pituitary adenomas subtypes: a tertiary referral center study
4
PubMed. Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study
5
The Journal of Clinical Endocrinology & Metabolism. Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers
6
PubMed Central. The Chance of Permanent Cure for Micro- and Macroprolactinomas, Medication or Surgery? A Systematic Review and Meta-Analysis
7
PubMed. Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
8
European Journal of Endocrinology. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
9
PubMed. The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study
10
European Journal of Endocrinology. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis
11
European Journal of Internal Medicine. Mortality in Cushing’s syndrome: A systematic review and meta-analysis
12
European Journal of Endocrinology. Mortality in Cushing’s syndrome: declining over 2 decades but remaining higher than the general population
13
PubMed Central. Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients
14
PubMed Central. Pituitary Carcinoma Diagnosis and Survival Improvement, with Affordable Care Act Correlation: A SEER Database Study
15
Endocrine Abstracts. Survival in patients with pituitary carcinoma
16
PubMed. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas
17
PubMed Central. Invasive adenoma and pituitary carcinoma: a SEER database analysis
18
Journal of Neurosurgery. Pituitary adenoma in the elderly: surgical outcomes and treatment trends in the United States
19
PubMed. Safety and Outcome of Transsphenoidal Pituitary Adenoma Resection in Elderly Patients
20
PubMed Central. Cavernous Sinus Involvement by Pituitary Adenomas: Clinical Implications and Outcomes of Endoscopic Endonasal Resection
21
PubMed. Characteristics and overall survival in pediatric versus adult pituitary adenoma: a National Cancer Database analysis
22
PubMed. Long-term outcomes of radiotherapy for pituitary adenomas
23
PubMed. Role of radiation therapy in clinical hormonally-active pituitary adenomas
24
PubMed Central. Long-term outcomes of modern radiation therapy for pituitary adenoma – different techniques: single institute experience
25
PubMed. The effect of hypopituitarism on life expectancy
26
Endocrine Reviews. Mortality in Patients with Pituitary Disease
27
PubMed. Life expectancy in patients with pituitary adenoma receiving growth hormone replacement
28
PubMed. Meta-analysis of mortality in adults with growth hormone deficiency: Does growth hormone replacement therapy really improve mortality rates?
29
PubMed. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas
30
PubMed. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas
31
PubMed Central. Evaluation of the potential of the Ki67 index to predict tumor evolution in patients with pituitary adenoma
32
PubMed Central. Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions
33
PubMed. Racial, ethnic, and socioeconomic disparities in pituitary surgery outcomes
34
PubMed Central. Socioeconomic Predictors of Pituitary Surgery
35
PubMed. Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies
36
PubMed Central. Long-Term Quality of Life Among Patients Undergoing Endoscopic Pituitary Gland Surgery
37
PubMed Central. Improving Quality of Life in Patients with Pituitary Tumours
38
PubMed. Frequent occurrence of pituitary apoplexy in patients with non-functioning pituitary adenoma